. Author manuscript; available in PMC: 2016 Jan 1.

Published in final edited form as: J Clin Gastroenterol. 2015 Jan;49(1):76–83. doi: 10.1097/MCG.0000000000000055

Table 3.

Self-Efficacy at Baseline and Treatment Week 24 as a Predictor of Ribavirin Missed Doses

	Baseline to Treatment Week 24 (N=384)				Treatment Week 24 to Treatment Week 48 (N=165)
	Unadjusted^a		Adjusted^b		Unadjusted^c		Adjusted^d

	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Global Self-Efficacy	0.98 (0.86, 1.11)	0.749	1.01 (0.86, 1.17)	0.926	0.95 (0.86, 1.12)	0.799	1.00 (0.80, 1.26)	0.999
Communication Self-Efficacy^†	0.95 (0.86, 1.10)	0.788	0.99 (0.88, 1.11)	0.856	0.95 (0.84, 1.07	0.400
Male							1.41 (0.92, 2.16	1.11
Female							45.4 (4.11, 501.6)	0.002
CESD=16							0.27 (0.05, 1.32)	0.105
CESD=23							0.13 (0.01, 1.16)	0.067
Physical Coping Self-Efficacy	1.00 (0.93, 1.08)	0.952	1.01 (0.93, 1.10)	0.744	1.01 (0.93, 1.10)	0.744	1.02 (0.90, 1.16)	0.754
Psychological Coping Self-Efficacy	1.02 (0.93, 1.11)	0.744	1.05 (0.94, 1.18)	0.420	1.00 (0.91, 1.11)	0.936	1.04 (0.88, 1.22)	0.659
Adherence Self-Efficacy	0.90 (0.79, 1.03)	0.170	0.92 (0.81, 1.05)	0.255	0.91 (0.77, 1.07)	0.275	0.94 (0.79, 1.11)	0.452

Note: OR: Odds Ratio; CI: Confidence Interval.

includes Baseline measures only;

adjusted for age, race, gender, insurance status, marital status, employment status, and baseline depression (CESD) score;

Treatment Week 24 Responders only;

Treatment Week 24 measures;

adjusted for age, race gender, insurance status, marital status, employment status, treatment week 24 CESD score;

^†

Treatment Week 24 (Adjusted) interactions between Communication Self-Efficacy and (1) gender, and (2) CESD (Nondepressed versus high) were significant at p<.10 level.